Fractyl Health Shares Rise Ahead of Upcoming Virtual Commercial Strategy Day
Fractyl Health (NASDAQ:GUTS) shares rose by 2.8% in pre-market trading ahead of its scheduled Virtual Commercial Strategy Day on September 1, 2026. The event is expected to outline the company's commercial strategy for Revita®, a procedural therapy designed to maintain weight loss after discontinuation of GLP-1 treatments. The announcement follows positive clinical data from Fractyl Health’s REMAIN-1 Midpoint Cohort study, which showed that patients receiving complete duodenal ablation with Revita maintained 84% of their previous GLP-1-induced weight loss compared to only 46% in the sham procedure group. The company estimates around 30 million U.S. adults use GLP-1 therapies and is positioning Revita as a one-time solution for those discontinuing these treatments. Analysts have issued mixed ratings, with Bank of America Securities giving a 'Buy' rating while Morgan Stanley maintains a 'Hold'. Fractyl Health also anticipates key clinical readouts in early Q4 2026 and aims to file an FDA De Novo marketing application by late Q4.
Tickers: $GUTS
Topics: analyst_ratings clinical_data_release commercial_strategy_day